(Reuters Health) - Court-ordered anti-smoking ads sponsored by the tobacco industry reached only around 40% of adults and about half of all smokers in the U.S., a recent study suggests.
AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.
An intervention used to treat astronauts has relevance for people on the ground with medical conditions that cause repeated fainting, researchers say.
Medical aesthetics company Evolus Inc on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's Botox, which has dominated the medical aesthetics market for more than a decade.
Aug 12 Evolus Inc on Monday reported
revenue of $2.3 million from early sales of its newly launched
rival to Allergan Plc's Botox, ahead of its own
(Reuters Health) - Researchers who examined implicit and explicit gender biases in the U.S. medical community found that professionals of both genders are more likely to associate the word "career" with men and the word "family" with women.
CVS Health Corp raised its full-year profit forecast and reported higher-than-expected second-quarter results on Wednesday, as increased U.S. prescription drug prices fueled rebates to its pharmacy benefits business.
Mallinckrodt Plc suspended plans to spin off its specialty generics unit, citing opioid litigation uncertainties, and warned Acthar gel revenue was unlikely to exceed $1 billion this year, sending its shares down about 15% on Tuesday.
(Reuters Health) - Universities across the United States have been slow to adopt anti-tobacco policies on campuses, researchers say, despite public health efforts to curb tobacco use, especially among teens and young adults.
Aug 1 Health insurer Cigna Corp raised
its 2019 profit forecast on Thursday, helped by last year's
acquisition of pharmacy benefit manager Express Scripts, but
medical costs in the second quarter were higher than expected
and its shares fell slightly.